Who's Aegerion going to partner with for distribution? They're not elligible for FH in Europe and will be competing with AMT for patients with LPL deficiency there. Seems unlikely that this will be a big market for them. They will also have competition from Isis for homozygous FH (mipomersen) and for distribution as an orphan drug since Isis has an agreement with Genzyme. A lot of uncertainties with this company that probably explain the lower than expected IPO price. Difficult to justify the recent low-volume increase in share price.
My estimation is that they're looking at $20 million per year revenues initially after 2012 if they get approval. Subtract R&D, SGA, and distribution expenses and there's not much left to justify the current valuation. Best case scenario is a buyout. Just my opinion.